Schizophrenia

In a nationwide cohort, clozapine shows the most mortality outcome benefit among schizophrenia antipsychotics.

New data shows that SEP-363856 curtails most of the debilitating side effects linked to current schizophrenia drugs.

In a new study, investigators found that 40 mg and 60 mg lumateperone is clinically safe to treat schizophrenia.

By screening during primary care visits, patients are now more aware than ever about their possibility of depression and other mental health disorders.

Lumateperone (Caplyta), a novel therapy, has received approval from the US FDA for the treatment of schizophrenia in adults.

Having a dog or cat in the first 12 years of a child's life could reduce the risk of serious psychiatric disorders later on.

Listen in to the audio transcript of a policy- and public health-based discussion on mental health stigma from a panel of experts.

How can clinicians and policy makers collaborate to improve the standing of mental health in the US?

A discussion with a director from the American Public Health Association on what drives the increasing burden of mental illness in the US.

How physicians in a shrinking field have taken on a greater burden of leadership roles in patient care.

How does psychiatry access differ among patients, and how should it become individualized?

The new transdermal patch offers a new delivery option for a well-established schizophrenia treatment.

In a comprehensive new study, investigators discover unique patterns in the brains of both family members and patients with psychotic disorders, including bipolar disorder and schizophrenia.

This week's #DocTalk tweet chat generated discussion on the means by which healthcare professionals can influence mental health policies and understanding.

A cohort study analysis shows clozapine is effective in treating schizophrenia, despite adverse effects.